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Background: Delayed M1 toward M2 macrophage phenotype transition is considered one of the major causes for
the impaired healing after myocardial infarction (MI). While searching for molecules that modulate M1 and M2
macrophage polarization, we identified collapsin response mediator protein-2 (CRMP2) as a novel molecule involved
in macrophage polarization to M1. In this study, we evaluated the effect of silencing CRMP2 on macrophage
polarization, inflammation and fibrosis post myocardial infarction.
Methods: CRMP2 expression was assessed with Western blotting or immunohistochemistry. Macrophage
phenotypes were measured with flow cytometry, quantitative real-time PCR (qPCR), Western blotting or
immunohistochemistry. CRMP2 siRNA was delivered into the macrophages infiltrated in the wound of ApoE−/− mice
through lipidoid nanoparticle, and fibrosis, leukocyte infiltration and inflammation parameters were measured with
qPCR. Infarct size was measured with Masson’s trichrome staining. Echocardiography was performed to assess
ventricular systolic dimension, left ventricular diastolic dimension, anterior wall thickness and posterior wall
thickness. Student’s t-test (for 2 groups) and ANOVA (for > 2 groups) were used for statistical analyses.
Results: CRMP2 was expressed in a higher level in M1 macrophages than M2 subsets, and CRMP2 RNA interference
(RNAi) resulted in a switch of bone marrow-derived macrophages from M1 to M2 phenotype. High level of CRMP2 was
also observed in the macrophages infiltrated in the infarct area 3 days post MI in both wildtype (WT) and ApoE−/− mice,
and the expression of CRMP2 retained in the infiltrated macrophages of ApoE−/− mice but not in that of WT mice
10 days after MI. Nanoparticle-mediated delivery of CRMP2 siRNA to ApoE−/− mice with MI resulted in dramatic switch
of wound macrophages from M1 to M2 phenotype, marked decrease in inflammation and fibrosis, and significant
attenuation of post-MI heart failure and mortality.
Conclusion: CRMP2 is highly expressed in M1 macrophages and silencing CRMP2 reprograms macrophage phenotype
and improves infarct healing in atherosclerotic mice.
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Myocardial infarction (MI) and the resulting complica-
tions are a major cause of death worldwide. Following
MI, circulating blood monocytes respond to chemotactic
factors, migrate into the infarct myocardium, and dif-
ferentiate into macrophages. At the injury site, macro-
phages remove necrotic cardiac myocytes and apoptotic
neutrophils; secrete cytokines, chemokines, and growth
factors; and modulate phases of the angiogenic response.
As such, macrophage is a primary responder cell type
that is involved in the regulation of post-MI wound hea-
ling at multiple levels. Two phases of infiltration are
defined after MI. In the first few days after injury, in-
flammatory monocytes and classical M1 macrophages
rapidly invade the wound to defend against pathogens,
phagocytose, and lyse debris, and thus pave the way for
tissue regeneration [1]. During subsequent healing,
classical macrophages retreat and give way to M2 mac-
rophages, which exhibit a less inflammatory panel of func-
tions that supports tissue repair and regeneration [2-4].
Recent studies have indicated that anti-inflammatory stra-
tegies targeting inflammatory monocyte/macrophage sub-
sets could reduce excessive inflammation and improve
cardiovascular outcomes [5-8]. Thus, identification of tar-
gets that modulate macrophage phenotypes and functions
may lead to development of novel therapeutic approaches
for MI.
In an effort of searching for molecules involved in
macrophage polarization, we established a phenotypic
screening assay and screened molecules that are able to
switch M1 to M2 using pooled shRNA library. Collapsin
response mediator protein-2 (CRMP2), a multifunctional
adaptor protein first described in the CNS and thoroughly
studied in neurons [9-11], was identified as a novel pro-
tein potentially involved in macrophage polarization.
CRMP2 belongs to a family of five homologous mem-
bers and was first identified as a mediator of semaphorin-
induced growth-cone collapse [10]. Downstream of
semaphorin signal, they reorganize the cytoskeleton by
controlling microtubule assembly [12-14], thereby play-
ing a crucial role in axonal outgrowth and neurite ex-
tension [10]. In recent years, several observations have
shown that CRMP2 is present in the immune system
and plays a critical role in T lymphocyte polarization
and migration [15-17]. CRMP2 has the ability to bind
to the cytoskeletal elements tubulin and vimentin redis-
tributed at the uropod, the flexible structure of T cells,
and RNA mediated crmp2/dpysl2 gene silencing and
blocking antibody strongly reduces T cell polarization
(uropod formation) and migration. Conversely, increased
CRMP2 expression promotes uropod formation and the
migration of transfected lymphocytes [16]. Thus, CRMP2
is a key player in cell behavior within a wider field than
just the nervous system.In the present study, we observed that CRMP2 was
expressed in a significantly higher level in M1 macro-
phages than M2 macrophage subsets, and knockdown of
CRMP2 with RNA interference (RNAi) in M1 macro-
phages resulted in a significant decrease in M1 gene ex-
pression and increase in M2 gene expression. High level
of CRMP2 was also observed in the macrophages infil-
trated in the infarct area 3 days post MI in both wildtype
(WT) and ApoE−/− mice, and the expression of CRMP2
retained in the infiltrated macrophages of ApoE−/− mice
but not in that of WT mice 10 days after MI. In ApoE−/−
mice with MI, nanoparticle-mediated delivery of CRMP2
siRNA to wound macrophages efficiently suppressed
expression of CRMP2 in vivo, associated with reduced
expression of inflammatory M1 macrophage markers,
increased resolution of inflammation, accelerated in-
farct healing, and attenuated fibrosis, development of
post-MI heart failure and mortality.
Materials and methods
Animal models
C57BL/6 J and B6.129P2-Apoetm1Unc/J (ApoE−/−) mice
used in this study were purchased from The Jackson
Laboratory (Bar Harbor, ME, USA). ApoE−/− mice were
fed on a high-cholesterol diet for 6 months (Harlan
Teklad, 0.2% total cholesterol). Myocardial infarction
was induced by permanent coronary ligation [18]. Briefly,
animals were anesthetized using a mixture of ketamine,
xylazine and atropine (100, 20 and 1.2 mg/kg, respectively,
i.p.) and mechanically ventilated. Under a surgical micro-
scope, left thoracotomy was performed to expose the
heart. The left coronary artery was identified and ligated
with a 7–0 silk suture at a level approximately 2 mm
below the edge of the left auricle. Sham operation was also
performed without ligating the coronary artery. After sur-
gery mice were monitored daily for 4 weeks and autopsy
was performed on all mice found dead to identify the
cause of death such as post-MI cardiac rupture or heart
failure, as described previously [18]. Some mice were
sacrificed at 6 and 24 h, 3, 7 and 14 days, and 4 weeks,
respectively, following MI. Infarct and non-infarct myo-
cardium were separated and snap frozen in liquid nitro-
gen and stored at −80°C for molecular assays. Further,
some hearts were fixed in 10% formalin or fresh frozen
for embedding with OCT for histological analyses. All
animal studies were approved by the Institutional Animal
Care and Use Committee (IACUC) of Ningxia Medical
University.
Culture of bone marrow-derived macrophages
Bone marrows were obtained from 8–12 week old C57BL/6
mice, and bone marrow-derived macrophages (BMDMs)
were cultured using a previously described protocol [19].
In brief, bone marrow cells were flushed out from mouse
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medium (DMEM; Gibco BRL, Shanghai, China) contain-
ing 100 μg/ml primocin (Invivogen, San Diego, CA, USA)
and then filtered through 100-μm cell strainer (BD,
Shanghai, China). Red blood cells were removed with
lysis buffer (0.75% NH4Cl, 0.02% Tris–HCl, pH 7.2) on
ice for 15 min. Bone marrow cells were cultured in a
DMEM supplement with 15% fetal calf serum (Sigma-
Aldrich, Shanghai, China) and 15% L929 conditioned
medium and seeded in 75-mm2 flasks at 37°C in 5%
CO2 incubator for 5 days. L929 is a murine fibroblast
cell line that produces M-CSF and has been used widely
for macrophage differentiation studies [20].
Activation of BMDMs
BMDMs were seeded in six-well plates at a density of
1 × 106 cells/well for overnight. Cells were then acti-
vated as follows: M1, IFN-γ (100 ng/ml; R&D Systems,
Shanghai, China) and LPS (50 ng/ml, Sigma-Aldrich);
M2a, IL-4 (20 ng/ml; R&D Systems, Shanghai, China);
M2b, immune complex (150 μg/ml anti-chicken egg al-
bumin (ovalbumin) monoclonal antibody preincubated
with 15 μg/ml ovalbumin at 37°C for 30 min, Sigma-
Aldrich) and LPS (50 ng/ml); and M2c, IL-10 (20 ng/ml,
R&D Systems). Seven and 24 h later, cells were harvested
for total RNA or protein extraction. Trypan blue staining
did not reveal significant cell death in activated BMDMs
at both time points. To collect the supernatants, cells were
activated with appropriate stimuli for 7 h. The cells were
then washed with phosphate-buffered saline (PBS) and in-
cubated with serum-free DMEM. Forty-eight hours later,
supernatants were collected and stored in −80°C until use.
Construct and RNA interference
Three CRMP-2 siRNAs (siCRMP-2-1, siCRMP-2-2 and
siCRMP-2-3) were designed to target mouse CRMP-2
mRNA (NM_009955) sequences: 5’-ACUCCUUCCUCG
UGUACA-3′, 5’-GAUGGGUUGAUCAAGCAA-3′ and
5’-ACTCCTTCCTCGTGTACAT-3’ respectively. A non-
targeting siRNA was used as a negative control for all
siRNA transfection experiments. All siRNAs were syn-
thesized by Shanghai GenePharma (Shanghai, China).
The efficacy and specificity of siRNAs were determined
as described previously [21].
Lipidoid-based siRNA formulations and
intravenous injection
Nanoparticles were prepared with the cationic lipid C12-
200, disteroylphosphatidyl choline, cholesterol, and PEG–
DMG using a spontaneous vesicle formation formulation
procedure [22]. In brief, lipids were dissolved in 90%
ethanol solution and mixed with siRNA solution (25 mM
citrate, pH 3 ratio) at fixed speed (1:1 ratio) and diluted
immediately with PBS to final 25% ethanol. The ethanolwas then removed and the external buffer replaced with
PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4,
pH 7.5) by dialysis. The final lipid:siRNA weight ratio
was ∼ 7:1. Particle size and zeta potential were determined
using a Malvern Zetasizer NanoZS (Malvern, UK). siRNA
content was determined by ion exchange HPLC (Agilent)
assay using DNAPac Pa200 column (Dionex Corporation
Dionex, 260 nm, 55°C run at 2 mL/min). siRNA entrap-
ment efficiency was determined by the Quant-iT Ribo-
Green RNA assay (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instruction. For intravenous injection,
mice were anesthetized and injected through the tail vein
with 0.5 mg/kg of either siCRMP2 or control siRNA
(siCON) incorporated into lipidoid nanoparticles (LNPs).
Plasmids and adenoviral infection
IRF expression construct was generated in the pENTR
vector (Invitrogen) modified to contain the CMV promoter
and IRES-linked GFP (pBent) as previously described
[23]. For delivery into mouse bone marrow-derived ma-
crophages, IRF5/luciferase cassettes were excised and
subcloned into the pBent vector, modified to contain
CMV-driven GFP in the orientation opposite to the lu-
ciferase gene and recombined into pAD/PL DEST vec-
tor (Invitrogen) for adenovirus production. Adenoviral
infections of mouse bone-marrow-derived macrophages
were performed in 96-well plates in triplicate. The
plates with serum-free RPMI medium 1640 containing
the desired number of viral particles were centrifuged
at 400 g for 30 min then placed at 37°C overnight. The
next day the virus media were replaced with 100 μL of
standard media and the cells were allowed to recover for
2 days before the application of experimental conditions.
Quantitative RT-PCR
Total messenger RNA (mRNA) was extracted using the
RNeasy Micro Kit (Qiagen) according to manufactu-
rer’s instructions. One microgram of mRNA was reverse
transcribed using the high capacity RNA to cDNA kit
(Applied Biosystems). TaqMan gene expression assays
(Applied Biosystems) were used to quantify target genes.
The relative changes were normalized to Gapdh mRNA
using the 2-ΔΔCTmethod.
Western blot analysis
Myeloid cells from heart tissue were isolated as described
above, washed with ice-cold PBS and homogenized on ice
using RIPA lysis buffer (Millipore) supplemented with
complete protease inhibitor cocktail (Roche). Protein
concentration was measured using BCA assay (Pierce).
Samples of 15 μg were loaded on 10% SDS-PAGE and
transferred onto PVDF membranes (Bio-Rad). Mem-
branes were blocked with 5% non fat dry milk in TBS-
Tween 0.1% and incubated with primary antibodies
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ondary antibodies. β-actin was used as control. Signals
were visualized with enhanced chemiluminescence de-
tection system (ECL Plus, Amersham Life Science), and
densitometric analysis was performed with ImageJ 1.40 g
(National Institutes of Health). The following antibodies
were used: rabbit polyclonal anti-CRMP2 (Abcam), rabbit
polyclonal anti-IRF5 (Abcam), mouse monoclonal anti-
IRF4 (eBioscience), rabbit polyclonal anti-IRF3 (Abcam),
rabbit monoclonal anti-CD86 (Abcam), rabbit polyclonal
anti-CD163 (Santa Cruz Biotechnology).
Histology
To eliminate blood contamination, hearts were perfused
with ice-cold PBS after mice were euthanized. Hearts
were removed, rinsed in PBS, embedded in O.C.T. com-
pound (Sakura Finetek), and frozen in an isopentane
bath on dry ice. For immunofluorescence staining, sec-
tions (5 μm) were stained with mixture of antibodies, in-
cluding mouse monoclonal anti-CD11b antibody (clone
M1/70, BD Biosciences) and a rabbit polycolonal anti-
iNOS (Abcam), mouse monoclonal anti-CD11b antibody
(BD Biosciences) and a rabbit polycolonal anti-IGF-1
(Abcam), or mouse monoclonal anti-CD11b antibody
(BD Biosciences) and a rabbit polycolonal anti-CRMP2
(Abcam), followed by incubation with a mixture of Alexa
Fluor® 488 Goat anti-mouse IgG and Cy3-conjugated
anti-rabbit IgG. The slides were cover slipped using a
mounting medium with DAPI (Vector Laboratories, Inc.)
to identify nuclei. Images were observed and captured
using Nikon Eclipse 80i with a Cascade Model 512 B
camera (Roper Scientific). For immunohistochemistry,
histology of the heart was performed on day 7 after MI
in ApoE−/− mice. Frozen sections (5 μm) were stained
for antibodies against CD11b (BD Biosciences), CD86
(Abcam), and CD206 (Abcam). The appropriate biotinyl-
ated secondary antibodies, ABC kit (Vector Laboratories,
Inc.) and AEC substrate (Dako) were used for color devel-
opment, and all the sections were counterstained with
Harris hematoxylin. The slides were scanned by a digital
slide scanner, NanoZoomer 2.0-RS in 40x high reso-
lution mode (Hamamatsu, Japan). The positive area was
quantified using IPLab (version 3.9.3; Scanalytics, Inc.)
and analyzing five high power fields per section and per
animal.
Postmortem histological determination of scar area
Mice were euthanized by cervical dislocation after anes-
thesia with 5% isoflurane for histological assay at 4 weeks
after MI [24]. Hearts were embedded in paraffin after
being fixed in 4% paraformaldehyde. Serial sections
(5 mm thickness) were performed Masson’s trichrome
stain to detect scar area and fibrosis in cardiac muscle.
Computerized morphometry was used to calculate thescar extent as the ratio of scar and total left ventricular
area using Imaging Pro Plus software.
Echocardiographic studies of cardiac function
Echocardiography was performed to assess the cardiac
function after MI in a blinded manner [25]. At 2 days
post operation (POD) and weekly until sacrificed, Mice
were anesthetized (2% isoflurane and oxygen) and put in
a supine position. Both two-dimensional and M-mode
images were recorded using a 30-MHz transducer. Left
ventricular systolic dimension (LVDs), left ventricular
diastolic dimension (LVDd), anterior wall thickness (AWT)
and posterior wall thickness (PWT) were measured to
calculate left ventricular ejection fraction (LVEF) and
fractional shortening (FS) as an average of three beats.
Statistics
Data are expressed as mean ± sem. Analyses were per-
formed using Prism 6.0a (GraphPad Software Inc.). The
group means were compared using a Student’s t-test (for
2 groups) and ANOVA, followed by Bonferroni post-
tests (for > 2 groups). P values of <0.05 indicate statis-
tical significance.
Results
M1 macrophages expressed higher level of CRMP2 than
M2 subsets
Before examine the expression of CRMP2 in different sub-
sets of macrophages, we first confirmed the phenotypes of
polarized BMDMs by measuring their distinct gene ex-
pression profile using real-time RT-PCR (Figure 1A).
IFN-γ and LPS-induced M1 macrophages expressed
high levels of iNOS and IL-12p40 but low level of IL-10
and arginase-1 (Arg1) (Figure 1B). M2a macrophages
(induced by IL-4) expressed high levels of Arg1 but low
levels of iNOS and IL-12p40 (Figure 1A). M2b macro-
phages (treated with immune complex and LPS) also
expressed iNOS and IL-12p40 but at lower levels as
compared to M1 macrophages (Figure 1A). M2c mac-
rophages (induced by IL-10) expressed CD163 but not
iNOS, and very low IL-12p40 (Figure 1A). These re-
sults, consistent with the previous reports [26], indica-
ted successful polarization of BMDMs to M1 and M2
subsets. We next examined the expression of CRMP2
in different subsets of macrophages using Western blot
analysis. As shown in Figure 1B, CRMP2, exhibiting
two major products with apparent molecular mass of
58 and 62 kDa, was detected in all subsets of macrophages
but with remarkably higher level in M1 than in M2 sub-
types. Using primary neuronal cultures for Western
blotting, we also detected two bands as shown in the
immunoblots of CRMP2 in macrophages, thereby con-
firming the expression of CRMP2 in macrophages. While
the 62 kDa product corresponds to the native protein







































Figure 1 Expression of CRMP2 in BMDM subsets. A. BMDMs
were incubated with IFN-γ + LPS (M1), IL-4 (M2a), IC+ LPS (M2b), or
IL-10 (M2c) for 7 h. The mRNA levels of iNOS, IL12p40, Arg-1, and
CD163 genes were detected by qPCR. Data mean ± SEM of gene
fold changes against untreated M0 cells. ***P < 0.001 vs. untreated
M0 cells. B. Western blot analysis of CRMP2 with a specific antibody
showed higher level of CRMP2 expression in M1 versus M2 and M0
macrophage subsets. The immunoblots of β-actin was used as
a loading control. Shown are representative data from three
independent experiments with similar results.
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band is likely the proteolytic cleavage. We also examined
the expression of CRMP1 and CRMP3-5 in macrophages
and found that very low level of these CRMPs was de-
tected and their expression was not changed during the
differentiation and polarization of macrophages (data not
shown). Thus, these data suggest that CRMP2 is specific-
ally expressed in M1 macrophages.
Knockdown of CRMP2 converted BMDMs from M1 to M2
macrophages
Given the higher level of CRMP2 expression in M1 than
M2 macrophages, we attempted to examine whether
CRMP2 RNAi in M1 macrophages affects their pheno-
type. M1 BMDMs were transfected with three different
CRMP2 siRNAs and levels of CRMP2 were assessed
with Western blotting. As shown in Figure 2A, M1 mac-
rophages transfected with each of the three siRNAs
(siCRMP2-1, −2, and −3) exhibited markedly reduced ex-
pression of CRMP2 compared the cells transfected with
the control siRNA (siCON). Therefore, in the following
studies, a combination of the three siRNAs, exhibited as
siCRMP2, was used. Using flow cytometry, we observed
that CRMP2 RNAi resulted in a marked decrease in theexpression of CD86, a typical M1 macrophage marker,
and a marked increase of CD163, a typical marker of M2
macrophages [26] (Figure 2B). Moreover, by measuring
the expression profile of M1 and M2 macrophage genes,
we observed that CRMP2 RNAi resulted in decreased
expression of a panel of M1 genes, including ccr7, cox2,
tnf-α, cd86, il12b, and cxcl10, and in the increase of
a number of M2 genes, including ym1, arg-1, and il-10
(Figure 2C and D). Though more studies are needed
to further define the M2 subtype (M2a or M2c) that
was converted from M1 by the CRMP2 knockdown,
based on the increase in arg-1 expression, it is postu-
lated that CRMP2 knockdown may convert M1 to M2a
phenotype [27].
Downregulation of IRF5 was responsible for the CRMP2
RNAi-induced switch of M1 to M2 macrophages
To understand the mechanism underlying the modula-
tion of macrophage phenotype by CRMP2, we first ex-
amined whether CRMP2 RNAi affects the expression of
IRF5, a transcription factor known to play a key role in
promoting macrophage polarization to M1 [23]. Western
blotting of IRF5 exhibited a major product with the mo-
lecular mass of 56 kDa, and CRMP2 knockdown resulted
in a marked decrease in the level of IRF5. However, the
expression of IRF4, which controls M2 polarization in
mice [28], was not affected by CRMP2 knockdown in the
M1 macrophages. The expression of IRF3, another mem-
ber of the IRF family central to the innate immune re-
sponse, was not affected by CRMP2 knockdown as well.
These data suggest that CRMP2 RNAi resulted in a spe-
cific down-regulation of IRF5 in M1 macrophages.
To explore the possible involvement of IRF5 in the re-
gulatory role of CRMP2 in macrophage polarization, M1
macrophages were transfected with control or CRMP2
siRNA before being infected with adenoviral constructs
containing IRF5 cDNA, and M1/M2 markers were as-
sessed with Western blotting. As shown in Figure 3B,
CRMP2 RNAi resulted in decreased expression of CD86
but increased expression of CD163, which was reversed
by the IRF5 overexpression.
CRMP2 was expressed in M1 macrophages infiltrated in
the infarct area in both WT and ApoE−/− mice with MI
To examine whether CRMP2 is expressed in M1 macro-
phages in vivo, we chose mouse MI model in which M1
macrophages rapidly invade the wound in the first few
days after the injury [1]. In addition to wildtype mice,
ApoE−/− mice on a high-fat diet were also used to gene-
rate MI model. These atherosclerotic mice have impaired
resolution of inflammation post-coronary ligation, due to
increased and prolonged recruitment of inflammatory
monocytes to the heart [29]. The delayed M1 and M2 tran-







































Figure 2 CRMP2 RNAi promoted M1 to M2 switch. A. Western blot analysis indicated that knockdown of CRMP2 with three siRNAs in M1
macrophages resulted in marked decrease in the expression of CD86 but increase in the expression of CD163. Shown are representative data
from three independent experiments with similar results. B. Flow cytometry images showed that CRMP2 RNAi with a mixture of three siRNAs in
M1 macrophages resulted in a marked decrease in the expression of CD86 but an increase in the expression of CD163. Shown are representative
data from three independent experiments with similar results. C & D. Gene expression analysis of selected M1- and M2-associated transcripts in














Figure 3 IRF5 was involved in CRMP2-mediated polarization of
macrophages. A. Representative immunoblots showed that CRMP2
RNAi in M1 macrophages resulted in a decrease in IRF5 expression,
without affecting the expression of IRF3 and IRF4. B. Representative
immunoblots showed that CRMP2 RNAi in M1 macrophages
resulted in decreased expression of CD86 but increased expression
of CD163, which were reversed by the overexpression of IRF5.
Shown are representative data from three independent experiments
with similar results.
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M2 macrophages markers were assessed on 3 and 10
days after MI, respectively. Immunostaining of macro-
phage markers indicated that the majority of macro-
phages infiltrated in the wound on day 3 after MI were
M1 macrophages (CD11b+ and iNOS+) in both wildtype
and ApoE−/− mice. However, on day 10 after MI, the
majority of macrophages infiltrated in the wound were
M2 (CD11b+ and IGF-1+) in wildtype mice but M1 in
ApoE−/− mice (Figure 4A-D). These data confirm the
notion that M1 macrophages dominate the wound in both
the inflammatory and resolution phases post MI. We then
examined the expression of CRMP2 in the macrophages
infiltrated in the wound. As shown in Figure 4E-G, in
ApoE−/− mice with MI, the majority of macrophages infil-
trated in the wound expressed CRMP2 on both day 3 and
day 10, whereas in WT mice, CRMP2 was expressed in
macrophages 3 days after MI, but was modestly expressed
in macrophages 10 days after MI. Within the macro-
phages, CRMP2 was distributed at one pole outside of
the nucleus (Figure 4E, arrows indicated). The immu-



































































































































Day 3            Day 10 
Figure 4 CRMP2 was predominantly expressed in M1 but not M2 macrophages infiltrated in the wound of wildtype and ApoE−/− mice
with MI. A & B. Representative confocal microscopy images showed the predominance of M1 (CD11b+, iNOS+) macrophages 3 days after MI
in both wildtype and ApoE−/− mice with MI, and predominance of M2 (CD11b+, IGF-1+) macrophages in wildtype but predominance of M2
(CD11b+, IGF-1+) macrophages in ApoE−/− mice 10 days after MI. Scale bar indicates 50 μm. C. Quantitation of M1 (CD11b+, iNOS+) macrophages
in the wound 3 and 10 days after MI. D. Quantitation of M2 (CD11b+, IGF-1+) macrophages in the wound 3 and 10 days after MI. E. Representative
confocal microscopy images showed the expression of CRMP2 in the infiltrated macrophages 3 days after MI in ApoE−/− mice. Arrows indicated
localization of CRMP2 in one pole outside of the nucleus. F. Representative confocal microscopy images showed the expression of CRMP2 in the
infiltrated macrophages 3 days after MI in WT mice. G. Quantitation of CRMP2 positive macrophages in the wound 3 and 10 days after MI in WT
and ApoE−/− mice. In all of the quantitative experiments, n = 4 mice per group and n = 4 high power fields (hpf). Data are mean ± SEM. *P < 0.05
compared to WT control.
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when the sections were stained with a control IgG (data
not shown). These data suggest that CRMP2 is pre-
dominantly expressed in M1 macrophages in the lesion
area of MI mice, consistent with its expression pattern
in macrophage cultures.
CRMP2 gene silencing resulted in M1 to M2 switch in
macrophages infiltrated in the infarct of ApoE−/− mice
with MI
To knockdown of CRMP2 in macrophages in vivo, siRNA
targeting CRMP2 was delivered to wound macrophages
after incorporation into lipidoid nanoparticles [22], which
were injected intravenously. Treatment with siCRMP2 in
the atherosclerotic mice with MI resulted in efficientknockdown of CRMP2 expression in macrophages on day
3 after MI (Figure 5A and B). Similar changes were also
observed on day 7 and 10 after MI (Figure 5B). To deter-
mine whether silencing CRMP2 can change macrophage
polarization, we evaluated the populations of CD11b+,
CD86+, and CD206+ positive cells, representing total mac-
rophages, M1 macrophages and M2 macrophages, re-
spectively using immunohistochemistry. On day 3 after
MI in the ApoE−/− mice, CRMP2 silencing resulted in a
marked decrease in M1 macrophages (Figure 5A and D)
and a marked increase in M2 macrophages (Figure 5A
and E) compared to the control siRNA treatment, whereas
total macrophages did not differ significantly between the
two treatments (Figure 5A and C). Similar changes were
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Figure 5 Silencing CRMP2 promoted macrophage polarization to M2 in the wound of ApoE−/− mice with MI. A. Representative confocal
microscopy images showed marked decrease in the expression of CRMP2 in the infiltrated macrophages, in the population of M1 (CD86 positive
cells), and in the increase in the population of M2 (CD206 positive cells) in the siCRMP2-treated ApoE−/− mice 3 days after MI. Scale bar indicates
50 μm B-E. Quantitation of CRMP2+ macrophages (CD11b+ and CRMP2+), total macrophages (CD11b+), M1 macrophages (CD86+), and M2
macrophages (CD206+) in the wound 3, 7 and 10 days after MI in ApoE−/− mice. n = 4 mice per group and n = 4 high power fields (HPF). Data
are mean ± SEM; **p < 0.01 compared to control.
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accelerated resolution of inflammation in ApoE−/− mice
To determine whether silencing CRMP2 affects in-
flammation resolution and fibrosis, we analyzed different
fibrosis and inflammation parameters by quantitative
real-time PCR in the infarct region, border zone, and
myocardial area remote to the infarct on day 7 and 28,
respectively. The cardiac fibroblast proliferation marker
Thy110 was strongly induced in the infarct region and
border zone by 7 days after injury in siCON-treated
mice, but was significantly lower in the siCRMP2 treated
mice (Figure 6A). Both collagen 1α1 and lysyl oxidase
were strongly induced in the infarct region and border
zones in the siCON treated mice, particularly 7 days
after infarction when the scar is being formed (Figure 6B
and C). Silencing CRMP2 decreased the expression of
these markers in the infarct region 28 days after surgery.
In the border zone, a significant reduction could already
be seen by 7 days. In the control siRNA treated animals,
expression of fibrotic markers was also detected in the
remote myocardial area, indicating the induction of inter-
stitial fibrosis, although the expression was much lower
than in the infarct region (Figure 6A-C). Animals treated
with siCRMP2 showed lower levels of collagen 1α1 and
lysyl oxidase in this area as well (Figure 6B and C).
We next analyzed the expression of different leukocyte
population markers and inflammatory mediators. To de-
termine the presence of neutrophils and macrophages,
we measured the expression of granzyme B and CD68,respectively. We observed robust expression of both
markers at 7 days after injury in the infarct region and
border zone of both siCON- and siCRMP2-treated mice
(Figure 6D and E). However, whereas expression of both
granzyme B and CD68 was almost normalized in the
border zone at 28 days in both groups, elevated expres-
sion persisted in the infarct region in the siCON-treated
mice. Notably, levels of these markers were significantly
lower in the infarct region of the siCRMP2-treated mice,
suggesting a faster resolution of inflammation in these
mice compared with the control group. Similarly, we ob-
served a strong induction of the proinflammatory cyto-
kine interleukin-6 in the infarct region and border zone
of the siCON-treated mice 7 and 28 days after injury,
but the IL-6 level was significantly lower in the siCRMP2-
treated animals (Figure 6F). Collectively, these results
indicate that silencing CRMP2 decreases fibrosis and
accelerates the resolution of inflammation after myo-
cardial infarction.
Silencing CRMP2 reduced the extent of myocardial injury
and decreased the mortality following MI in ApoE−/− mice
To study the effects of CRMP2 knockdown in macro-
phages on the extent of fibrosis after MI, we performed
Masson’s trichrome staining. As illustrated in Figure 7A,
severe fibrosis was observed in the hearts of siCON
group with MI, but treatment with siCRMP2 markedly
reduced cardiac fibrosis. Quantitative measurement re-
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Figure 6 CRMP2 RNAi reduced the expression of fibrosis and inflammation markers in ApoE−/− mice with MI. Expression of different
fibrosis and inflammation markers was analyzed by quantitative real-time PCR in myocardial samples from the infarct region (Infarct), infarct
border zone (Border), and area remote to the infarct (Remote) 7 and 28 days after infarction. A. Fibroblast proliferation marker Thy1. B. Collagen
1a1 (Col1a1). C. Lysyl oxidase (Lox). D. Neutrophil marker granzyme B (Gzmb). E. Macrophage marker CD68. F. Proinflammatory cytokine
interleukin-6 (IL-6). Results are expressed as fold induction ± SE over the uninjured values. *P < 0.05 compared to siCON group.
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was 14.75 ± 3.12%, significantly less than that in the
siCON group (P < 0.05) (Figure 7B).
Furthermore, echocardiogram studies were performed
to evaluate the cardiac function after MI in both groups.
Serial echocardiographic analysis indicating that siCRMP2
treatment manifested a trend towards improvement of
cardiac performance after MI. Compared with sham
group, MI increased the LVEDd and LVESd in both
siCON and siCRMP2 groups, with significant less level
in siCRMP2 group than that in siCON group (Figure 7C
and D). Furthermore, the LVEF and FS were significantly
enhanced in siCRMP2 group compared with siCON
group (Figure 7E and F). These data suggested that
siCRMP2 treatment decreased fibrosis and preserved
cardiac function after MI. Moreover, the Kaplan–Meier
survival curves indicated that siCRMP2 treatment sig-
nificantly decreased the mortality after MI compared
with the siCON treatment (Figure 7G).Discussion
With the recent insight into the molecular mechanisms
governing macrophage heterogeneity, polarization and
function [31], it has become feasible to modulate ma-
crophage actions in interventions that might optimize
healing of injured tissues. Identification of appropriate
targets that modulate macrophages phenotypes is critical
for this goal. In the present study, we provided the first
evidence that CRMP2 is expressed in macrophages and
its expression depends on the activated status of the
cells. CRMP2 is predominantly expressed in M1 macro-
phages, and plays a role in macrophage polarization to
M1 as silencing CRMP2 results in switch of macro-
phages from M1 to M2 not only in vitro but also in ath-
erosclerotic mice with MI. Thus, modulation of CRMP2
expression may promote inflammation resolution and
improve infarct healing.
Macrophages are key mediators of the immune response
during inflammation. Plasticity and functional polarization
A
sham MI-siCON MI-siCRMP2










































0       2        7      14     21     28 0       2       7     14     21    28
Days after MI Days after MI
0        2       7      14     21     28






































* * ** * * *
*
*
Sham     MI-siCON
Figure 7 Effects of CRMP2 silence on left ventricular fibrosis and heart function after MI in ApoE−/− mice. A. Representative Masson’s
trichrome staining revealed left ventricular fibrosis 4 weeks after MI (magnification: 4x). Scale bar indicates 500 μm. B. Quantitative analysis of the
scar area (n = 10, *p < 0.05). C. Quantification of left ventricular end diastolic diameter (LVEDd). D. Quantification of left ventricular end systolic
diameter (LVESd), E. Quantification of left ventricular ejection fraction. F. Quantification of fractional shortening (n = 30, *p < 0.05 vs. control).
G. Kaplan–Meier survival curves in siCON and siCRMP2 groups with MI (n = 30 per group, *p < 0.05 vs. control).
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typic diversity of macrophage populations [32]. Though
many transcription factors, including PU.1, C/EBPβ,
Runx1 and IRF8, are involved in lineage-specific tran-
scriptional regulation during macrophage differentiation
[33], only a small proportion of the macrophage trans-
criptome is altered by cell polarization [34]. Among the
transcription factors, IRF5 is defined to determine com-
mitment to the M1 macrophage lineage [23]. Another
member of the IRF family, IRF4, known to inhibit IRF5 ac-
tivation by competing for interaction with the adaptor
Myd88, is reported to control the expression of prototyp-
ical mouse M2 macrophage markers [28]. We found that
knockdown of CRMP2 reduced the expression of a num-
ber of M1 genes, including ccr7, cox2, tnf-α, cd86, il12b
and cxcl10, and increased the expression of several M2
genes, including ym-1, arg-1, and il-10. These were associ-
ated with down-regulation of IRF5, without affecting theexpression of IRF3 and IRF4. We further demonstrated
that CRMP2-knockdown-induced M1 to M2 switch was
reversed by overexpression of IRF5 in M1 macrophages.
Therefore, it is postulated that CRMP2 may play a role in
modulating macrophage polarization to M1 through, at
least in part, regulating IRF5 expression. However, the
underlying mechanism remains to be elucidated. It is pos-
tulated that CRMP2, which is localized in both cytoplasm
and nucleus, may be directly involved in the transcrip-
tional regulation of IRF5 or physically interact with IRF5
thereby stabilizing IRF5. These hypotheses need to be
confirmed in future studies.
Enforcing the natural transition of M1 toward M2
macrophages in wounds may thus usher in resolution of
inflammation and speed healing, especially if acute wound
inflammation exists in the setting of an underlying chronic
inflammatory disease. A prolongation of the inflammatory
phase of wound healing inhibits regenerative processes
Zhou et al. Journal of Inflammation  (2015) 12:11 Page 11 of 12and may compromise tissue integrity. Coronary ligation in
ApoE−/− mice allows the study of MI in the context of
pre-existing chronic inflammation [29]. These atheroscler-
otic mice have impaired resolution of inflammation post-
coronary ligation due to delayed M1 and M2 transition
[30], thereby having a higher risk of developing heart fail-
ure post-MI, possibly due to compromised infarct healing
[35]. We observed a significantly prolonged infiltration of
M1 macrophages in the infarct of ApoE−/− mice compared
to that in wildtype mice. Intriguingly, the inflammatory
macrophages in the infarct wound expressed CRMP2,
which was localized at one pole outside of the nucleus.
To investigate the effect of CRMP2 knockdown on
infarct healing in ApoE−/− mice with MI, we used a lipi-
doid nanoparticle to deliver CRMP2 siRNA into the
wound because employing the endocytic machinery of
macrophages, intravenously administered nanoparticles
are rapidly taken up by monocytes/macrophages, and
accumulated in macrophages in atherosclerotic plaques
[36,37], rendering inflammatory myeloid cells a prime
target for in vivo RNAi [38-40]. In ApoE−/− mice with MI,
nanoparticle-mediated delivery of siRNAs has been shown
to efficiently knockdown the target genes in macrophages
in the infarct wound [18]. Consistently, we demonstrated
that nanoparticle-mediated delivery of CRMP2 siRNA re-
sulted in an efficient knockdown of CRMP2 in macro-
phages infiltrated in the wound. This was associated with
a significantly decreased proportion of M1 but markedly
increased proportion of M2 macrophages in the wound,
whereas total macrophage percentage did not differ be-
tween the control and CRMP2 siRNA groups. We showed
that in vivo knockdown of CRMP2 supported the reso-
lution of inflammation, as numbers of inflammatory cells,
including monocytes, neutrophils and macrophages were
reduced. Moreover, CRMP2 RNAi decreased the extent of
fibrosis, leading to an enhanced cardiac function recovery
and decreased the mobility after MI.
In conclusion, we show that CRMP2 plays a role in
macrophage polarization of M1 phenotype and CRMP2
RNAi resulted in a switch of M1 to M2 macrophages
not only in vitro but also in ApoE−/− mice with MI, lead-
ing to an promoted inflammation resolution, enhanced
cardiac function recovery and decreased mobility after MI.
Although our study bears some clinical relevance, the de-
tailed physiologic and pathologic functions of CRMP2
have not been extensively characterized. Further studies
defining the exact underlying mechanisms are needed.Abbreviations
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